Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China.

MLA

Shen, An-Le, et al. “Cost-Effectiveness Analysis of Dinutuximab β for the Treatment of High-Risk Neuroblastoma in China.” Pediatric Blood & Cancer, vol. 70, no. 12, Dec. 2023, p. e30680. EBSCOhost, https://doi.org/10.1002/pbc.30680.

APA

Shen, A.-L., Zhao, J., Yu, L.-T., Zhang, A.-A., Wu, B., Fang, Y., Han, Y.-L., Li, C.-S.-Z., Li, Z.-L., Gao, Y.-J., & Zhang, S.-G. (2023). Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China. Pediatric Blood & Cancer, 70(12), e30680. https://doi.org/10.1002/pbc.30680

Chicago

Shen, An-Le, Jie Zhao, Li-Ting Yu, An-An Zhang, Bin Wu, Ye Fang, Ya-Li Han, et al. 2023. “Cost-Effectiveness Analysis of Dinutuximab β for the Treatment of High-Risk Neuroblastoma in China.” Pediatric Blood & Cancer 70 (12): e30680. doi:10.1002/pbc.30680.